Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

Eur Urol. 2021 Mar;79(3):351-352. doi: 10.1016/j.eururo.2020.12.011. Epub 2021 Jan 9.

¹ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: nattakorn.dhiantravan@petermac.org.
² Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Abstract

Optimisation of prostate-specific membrane antigen (PSMA) based radioligand therapy (RLT) requires a focus on prospective trials.